Table 2 Risk factors for subsequent MRSA infection in MRSA nasal carrier cohorts
Variable | No. (%) | P | Adjusted OR (95% CI) | P | |
|---|---|---|---|---|---|
Patients with subsequent MRSA infection (n = 46) | Patients with no subsequent MRSA infection (n = 308) | ||||
Female gender | 16 (34.8) | 122 (39.6) | 0.531 | ||
Age, median (IQR) | 57.5 (41.0–67.0) | 52.5 (5.5–66.0) | 0.111 | ||
ST72 MRSA | 26 (56.5) | 172 (55.8) | 0.931 | ||
Reason for nasal MRSA screening | |||||
Transfer from other hospital | 24 (52.2) | 104 (33.8) | 0.015 | 2.375 (1.094–5.157 | 0.029 |
Pre-operative screening | 11 (23.9) | 108 (35.1) | 0.135 | ||
MRSA isolated from clinical specimens | 23 (50.0) | 9 (2.9) | <0.001 | 33.235 (13.102–84.303) | <0.001 |
Carriage of VRE | 2 (4.3) | 21 (6.8) | 0.752 | ||
Undergoing HD or CAPD | 3 (6.5) | 12 (3.9) | 0.425 | ||
Admission due to infection other than MRSA infection | 17 (37.0) | 54 (17.5) | 0.002 | 0.576 (0.240–1.387) | 0.219 |
Comorbidity | |||||
Solid tumor | 9 (16.9) | 63 (20.5) | 0.889 | ||
Cardiovascular | 10 (21.7) | 63 (20.5) | 0.841 | ||
Diabetes mellitus | 11 (23.9) | 47 (15.3) | 0.198 | ||
Liver disease | 6 (13.0) | 29 (9.4) | 0.442 | ||
Neurologic disease | 4 (8.7) | 40 (13.0) | 0.631 | ||
Chronic kidney disease | 8 (17.4) | 32 (10.4) | 0.162 | ||
Solid organ transplantation | 2 (4.3) | 8 (2.6) | 0.625 | ||
Chronic lung disease | 7 (15.2) | 8 (2.6) | 0.001 | 4.870 (1.193–19.872) | 0.027 |
Hematologic malignancy | 3 (6.5) | 12 (3.9) | 0.425 | ||
CAPD | 0 (0.0) | 3 (1.0) | 1.000 | ||
HSCT | 0 (0.0) | 1 (0.3) | 1.000 | ||
Severity of underlying disease | 0.335 | ||||
Rapidly fatal | 3 (6.5) | 11 (3.6) | |||
Ultimately fatal | 26 (56.5) | 152 (49.4) | |||
Nonfatal | 17 (37.0) | 145 (47.1) | |||